The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Feasibility of CAR-T in very old patients with relapsed/refractory diffuse large B-cell lymphoma.
 
Alon Rozental
No Relationships to Disclose
 
Julio C. Chavez
Honoraria - Adaptive Biotechnologies; Lilly
Consulting or Advisory Role - Abbvie; ADC Therapeutics; Adicet Bio; AstraZeneca; BMSi; Cellectar; Genmab; Janssen; Kite/Gilead; Novartis; TeneoBio
Speakers' Bureau - Epizyme
Research Funding - Adaptive Biotechnologies; AstraZeneca; Merck (Inst)
 
Marina Sehovic
No Relationships to Disclose
 
Frederick L. Locke
Consulting or Advisory Role - A2 Biotherapeutics; Alimera Sciences; Amgen; Bluebird Bio; Bristol-Myers Squibb; Bristol-Myers Squibb/Celgene; Calibr; Caribou Biosciences; Celgene; Cowen; Daiichi Sankyo/UCB Japan; EcoR1 Capital; Gerson Lehrman Group; Iovance Biotherapeutics; Janssen; Kite, a Gilead company; Legend Biotech; Miltenyi Biotec; Novartis; Sana Biotechnology; Takeda; Takeda; Umoja Biopharma; Umoja Biopharma
Research Funding - Alimera Sciences (Inst); Bluebird Bio (Inst); Bristol-Myers Squibb/Celgene (Inst); Kite, a Gilead company (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - CAR T Cells with Enhanced Metabolic Fitness. Serial Number: 62/939,727 (Inst); Double Mutant Survivin Vaccine. US010414810B2. (Inst); Evolutionary Dynamics of Non-Hodgkin Lymphoma CAR-T cell therapy. Serial Number: 62/879,534. (Inst); Methods of Enhancing CAR T Cell Therapies. Serial Number: 62/892,292. (Inst)
Travel, Accommodations, Expenses - A2 Biotherapeutics; Kite, a Gilead company
 
Aleksandr Lazaryan
Consulting or Advisory Role - Sanofi
Travel, Accommodations, Expenses - Sanofi
 
Taiga Nishihori
Research Funding - Karyopharm Therapeutics (Inst); Novartis (Inst)
 
Farhad Khimani
Research Funding - Bristol-Myers Squibb (Inst)
 
Michael D. Jain
Consulting or Advisory Role - Bristol-Myers Squibb; Kite/Gilead; Myeloid Therapeutics; Novartis
Research Funding - Incyte; Kite/Gilead
Travel, Accommodations, Expenses - Kite/Gilead
 
Bijal D. Shah
Honoraria - BeiGene; Gilead Sciences; Pharmacyclics/Janssen; Spectrum/Acrotech
Consulting or Advisory Role - Adaptive Biotechnologies; Amgen; Autolus; Bristol-Myers Squibb/Celgene; Century Therapeutics; Deciphera; Jazz Pharmaceuticals; Kite, a Gilead company; Lilly; Novartis; Pepromene; Pfizer; Pfizer; Precision Biosciences
Research Funding - Incyte; Jazz Pharmaceuticals (Inst); Kite/Gilead (Inst); SERVIER (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Celgene; Janssen; Kite, a Gilead company; Novartis; Pfizer; Seagen; Stemline Therapeutics
 
Martine Extermann
Honoraria - OncLive Clinical Congress Consultants
Consulting or Advisory Role - Aileron Therapeutics; Alnylam